Trial Profile

First in Human, Phase Ia/Ib Study for Safety, Tolerability, Pharmacokinetics, and Clinical Activity Evaluation of ADEL-Y01 in Healthy Participants and in Participants with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 05 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Apr 2026 Status changed from suspended to discontinued due to sponsor transition and strategic decision not to continue the protocol.
25 Mar 2026 Status changed from recruiting to suspended.
18 Nov 2025 Planned End Date changed from 28 Feb 2026 to 31 Jul 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com